Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells

Journal of Immunology

Volumn 194, Issue 3, 2015, Pages 940-949

  Ratliff, Michelle L ^a   Ward, Julie M ^a,b   Merrill, Joan T ^a   James, Judith A ^a,b   Webb, Carol F ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH INTERACTING DOMAIN PROTEIN 3A; CD34 ANTIGEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; ARID3A PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE ANTIGEN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CELL MATURATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; B LYMPHOCYTE; CASE CONTROL STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; SCID MOUSE; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODY FORMATION; ANTIGENS, SURFACE; B-LYMPHOCYTES; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84921535624     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401941     Document Type: Article

References (59)

1. Ichii, M., M. B. Frank, R. V. Iozzo, and P. W. Kincade. 2012. The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood 119: 1683-1692.
2. Fu, S., and J. Liesveld. 2000. Mobilization of hematopoietic stem cells. Blood Rev. 14: 205-218.
3. Tyndall, A. 2011. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am. Soc. Hematol. Educ. Program 2011: 280-284.
4. Shepard, K. A., and S. Talib. 2014. Bottlenecks in deriving definitive hematopoietic stem cells from human pluripotent stem cells: a CIRM mini-symposium and workshop report. Stem Cells Transl. Med. 3: 775-781.
5. Moonen, J. R., K. de Leeuw, X. J. van Seijen, C. G. Kallenberg, M. J. van Luyn, M. Bijl, and M. C. Harmsen. 2007. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 9: R84.
6. Westerweel, P. E., R. K. Luijten, I. E. Hoefer, H. A. Koomans, R. H. Derksen, and M. C. Verhaar. 2007. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann. Rheum. Dis. 66: 865-870.
7. Niu, H., G. Fang, Y. Tang, L. Xie, H. Yang, L. Morel, B. Diamond, and Y. R. Zou. 2013. The function of hematopoietic stem cells is altered by both genetic and inflammatory factors in lupus mice. Blood 121: 1986-1994.
8. Kortschak, R. D., P. W. Tucker, and R. Saint. 2000. ARID proteins come in from the desert. Trends Biochem. Sci. 25: 294-299.
9. Patsialou, A., D. Wilsker, and E. Moran. 2005. DNA-binding properties of ARID family proteins. Nucleic Acids Res. 33: 66-80.
10. Wilsker, D., L. Probst, H. M. Wain, L. Maltais, P. W. Tucker, and E. Moran. 2005. Nomenclature of the ARID family of DNA-binding proteins. Genomics 86: 242-251.
11. Webb, C. F., C. Das, R. L. Coffman, and P. W. Tucker. 1989. Induction of immunoglobulin mu mRNA in a B cell transfectant stimulated with interleukin-5 and a T-dependent antigen. J. Immunol. 143: 3934-3939.
12. Webb, C. F., C. Das, S. Eaton, K. Calame, and P. W. Tucker. 1991. Novel protein-DNA interactions associated with increased immunoglobulin transcription in response to antigen plus interleukin-5. Mol. Cell. Biol. 11: 5197-5205.
13. Rajaiya, J., M. Hatfield, J. C. Nixon, D. J. Rawlings, and C. F. Webb. 2005. Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright. Mol. Cell. Biol. 25: 2073-2084.
14. Rajaiya, J., J. C. Nixon, N. Ayers, Z. P. Desgranges, A. L. Roy, and C. F. Webb. 2006. Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Mol. Cell. Biol. 26: 4758-4768.
15. Nixon, J. C., S. Ferrell, C. Miner, A. L. Oldham, U. Hochgeschwender, and C. F. Webb. 2008. Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells. J. Immunol. 181: 6913-6922.
16. Webb, C. F., J. Bryant, M. Popowski, L. Allred, D. Kim, J. Harriss, C. Schmidt, C. A. Miner, K. Rose, H. L. Cheng, et al. 2011. The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development. Mol. Cell. Biol. 31: 1041-1053.
17. Webb, C. F., E. A. Smith, K. L. Medina, K. L. Buchanan, G. Smithson, and S. Dou. 1998. Expression of bright at two distinct stages of B lymphocyte development. J. Immunol. 160: 4747-4754.
18. Nixon, J. C., J. B. Rajaiya, N. Ayers, S. Evetts, and C. F. Webb. 2004. The transcription factor, Bright, is not expressed in all human B lymphocyte subpopulations. Cell. Immunol. 228: 42-53.
19. Oldham, A. L., C. A. Miner, H. C. Wang, and C. F. Webb. 2011. The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production. Mol. Immunol. 49: 367-379.
20. Nuttall, A., and D. A. Isenberg. 2013. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. Best Pract. Res. Clin. Rheumatol. 27: 309-318.
21. Ward, J. M., K. Rose, C. Montgomery, I. Adrianto, J. A. James, J. T. Merrill, and C. F. Webb. 2014. Disease activity in lupus correlates with expression of the transcription factor ARID3a. Arthritis Rheum. 2014: 3.
22. Doulatov, S., F. Notta, E. Laurenti, and J. E. Dick. 2012. Hematopoiesis: a human perspective. Cell Stem Cell 10: 120-136.
23. Hochberg, M. C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725.
24. Notta, F., S. Doulatov, E. Laurenti, A. Poeppl, I. Jurisica, and J. E. Dick. 2011. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 333: 218-221.
25. Ichii, M., K. Oritani, T. Yokota, Q. Zhang, K. P. Garrett, Y. Kanakura, and P. W. Kincade. 2010. The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage. PLoS One 5: e12954.
26. Ichii, M., K. Oritani, T. Yokota, D. C. Schultz, J. L. Holter, Y. Kanakura, and P. W. Kincade. 2010. Stromal cell-free conditions favorable for human B lymphopoiesis in culture. J. Immunol. Methods 359: 47-55.
27. -/- mice: a promising model for studying human disease. Arthritis Rheum. 63: 2764-2773.
28. Shankar, M., J. C. Nixon, S. Maier, J. Workman, A. D. Farris, and C. F. Webb. 2007. Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor Bright. J. Immunol. 178: 2996-3006.
29. - common lymphoid progenitor stages in two pro-B-cell development pathways. Proc. Natl. Acad. Sci. USA 107: 5925-5930.
30. null mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun. 13: 399-410.
31. null (NSG) mice conditioned by busulfan. J. Clin. Immunol. 31: 253-264.
32. null mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS ONE 7: e35497.
33. Shultz, L. D., B. L. Lyons, L. M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. Kotb, S. D. Gillies, M. King, J. Mangada, et al. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rg null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174: 6477-6489.
34. Randall, T. D., and I. L. Weissman. 1997. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89: 3596-3606.
35. Cheshier, S. H., S. S. Prohaska, and I. L. Weissman. 2007. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. 16: 707-717.
36. Rodriguez, S., A. Chora, B. Goumnerov, C. Mumaw, W. S. Goebel, L. Fernandez, H. Baydoun, H. HogenEsch, D. M. Dombkowski, C. A. Karlewicz, et al. 2009. Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood 114: 4064-4076.
37. Park, S. J., D. H. Yoon, S. Kim, K. Lee, J. S. Park, S. Jang, C. J. Park, H. S. Chi, C. S. Park, J. Huh, and C. Suh. 2014. Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines. Transfusion 54: 509-515.
38. To, L. B., J. P. Levesque, and K. E. Herbert. 2011. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 118: 4530-4540.
39. Montecino-Rodriguez, E., H. Leathers, and K. Dorshkind. 2006. Identification of a B-1 B cell-specified progenitor. Nat. Immunol. 7: 293-301.
40. Hardy, R. R., and K. Hayakawa. 2012. Positive and negative selection of natural autoreactive B cells. Adv. Exp. Med. Biol. 750: 227-238.
41. -. J. Exp. Med. 208: 67-80.
42. Tangye, S. G. 2013. To B1 or not to B1: that really is still the question! Blood 121: 5109-5110.
43. Herrscher, R. F., M. H. Kaplan, D. L. Lelsz, C. Das, R. Scheuermann, and P. W. Tucker. 1995. The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev. 9: 3067-3082.
44. Lin, D., G. C. Ippolito, R. T. Zong, J. Bryant, J. Koslovsky, and P. Tucker. 2007. Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Mol. Cancer 6: 23.
45. An, G., C. A. Miner, J. C. Nixon, P. W. Kincade, J. Bryant, P. W. Tucker, and C. F. Webb. 2010. Loss of Bright/ARID3a function promotes developmental plasticity. Stem Cells 28: 1560-1567.
46. Popowski, M., T. D. Templeton, B.-K. Lee, C. Rhee, H. Li, C. Miner, J. D. Dekker, S. Orlanski, Y. Bergman, V. R. Iyer, et al. 2014. Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog. Stem Cell Rev. 2: 26-35.
47. Fukuyo, Y., K. Mogi, Y. Tsunematsu, and T. Nakajima. 2004. E2FBP1/hDril1 modulates cell growth through downregulation of promyelocytic leukemia bodies. Cell Death Differ. 11: 747-759.
48. INK4A-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability. Int J Oral Sci 3: 200-208.
49. Baldridge, M. T., K. Y. King, and M. A. Goodell. 2011. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 32: 57-65.
50. Esplin, B. L., T. Shimazu, R. S. Welner, K. P. Garrett, L. Nie, Q. Zhang, M. B. Humphrey, Q. Yang, L. A. Borghesi, and P. W. Kincade. 2011. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J. Immunol. 186: 5367-5375.
51. Alchi, B., D. Jayne, M. Labopin, A. Demin, V. Sergeevicheva, T. Alexander, F. Gualandi, B. Gruhn, J. Ouyang, P. Rzepecki, et al. 2013. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 22: 245-253.
52. Illei, G. G., R. Cervera, R. K. Burt, A. Doria, F. Hiepe, D. Jayne, S. Pavletic, T. Martin, A. Marmont, R. Saccardi, et al. 2011. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann. Rheum. Dis. 70: 2071-2074.
53. Sui, W., X. Hou, W. Che, J. Chen, M. Ou, W. Xue, and Y. Dai. 2013. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin. Immunol. 148: 186-197.
54. Beksac, M., and F. Preffer. 2012. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? Bone Marrow Transplant. 47: 1391-1396.
55. Hakim, O., M. H. Sung, S. Nakayamada, T. C. Voss, S. Baek, and G. L. Hager. 2013. Spatial congregation of STAT binding directs selective nuclear architecture during T-cell functional differentiation. Genome Res. 23: 462-472.
56. Heng, T. S., M. W. Painter, Immunological Genome Project Consortium. 2008. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9: 1091-1094.
57. Garcia-Romo, G. S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, C. Guiducci, R. L. Coffman, et al. 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20.
58. Lande, R., D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. Chamilos, R. Sebasigari, V. Riccieri, et al. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra19.
59. Villanueva, E., S. Yalavarthi, C. C. Berthier, J. B. Hodgin, R. Khandpur, A. M. Lin, C. J. Rubin, W. Zhao, S. H. Olsen, M. Klinker, et al. 2011. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187: 538-552.